Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Repros receives FDA guidance regarding phase II study in endometriosis

July 17, 2012

Encouraging results reported from phase I trial of ALN-TTR02

July 17, 2012

Scientists at Roche disclose new HDL cholesterol-raising agents

July 17, 2012

In vivo results for ARRY-981 presented

July 16, 2012

Intranasal CP-024 leads to IGF-I induction in healthy volunteers

July 16, 2012

New fusion protein from Bristol-Myers Squibb demonstrates antidiabetic activity

July 16, 2012

Japanese team discloses novel treatments for diabetes

July 16, 2012

Orexigen Therapeutics reports early enrollment in the Light study

July 13, 2012

GSK receives final phase III data for albiglutide

July 13, 2012

Merck & Co. provides update on phase III odanacatib trial

July 13, 2012

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...